PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Owner Earnings per Share (TTM): 0.00 (As of Dec. 2025)


CAS:PRO PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO
85 GF Score
Price MAD1,349.00
GF Value MAD1,331.32
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Owner Earnings per Share (TTM)?

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO 85 Owner Earnings per Share (TTM) is 0.00 as of Dec. 2025. GuruFocus rates CAS:PRO with a GF Score™ of 85/100 and a GF Value™ of MAD1,331.32 (Fairly Valued). The stock has 6 warning signs investors should review. Among 472 Drug Manufacturers companies, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks worse than 211864.19% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM does not have enough data to calculate Owner Earnings per Share (TTM), so as Price-to-Owner-Earnings ratio.


The historical rank and industry rank for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Owner Earnings per Share (TTM) or its related term are showing as below:



CAS:PRO's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 23.775
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was MAD0.00. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was MAD0.00. It's PE Ratio (TTM) ratio for today is N/A.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's EPS without NRI for the six months ended in Dec. 2025 was MAD0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was MAD0.00. It's PE Ratio without NRI ratio for today is N/A.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Owner Earnings per Share (TTM) Related Terms


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Owner Earnings per Share (TTM) Chart

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CAS:PRO vs ZTS, UTHR, VTRS: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Price-to-Owner-Earnings falls into.


CAS:PRO
85GF Score
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM does not have enough data to calculate Owner Earnings per Share (TTM). Please check Wal-Mart Stores Inc, as your reference.

What does a Owner Earnings per Share (TTM) of 0.00 mean?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a Owner Earnings per Share (TTM) of 0.00 as of Dec. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM. According to the industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #999999 out of 472 companies in the Drug Manufacturers industry.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Owner Earnings per Share (TTM) too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Owner Earnings per Share (TTM) is 0.00. Based on the distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #999999 out of 472 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Owner Earnings per Share (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #999999 out of 472 companies for Owner Earnings per Share (TTM). This places PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 23.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 23.78, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 23.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Owner Earnings per Share (TTM) is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,331.32, compared to a current price of MAD1,349.00 — trading 1.3% above its estimated fair value. The current Owner Earnings per Share (TTM) is 0.00. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current Owner Earnings per Share (TTM) is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?

Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued. The current stock price of MAD1,349.00 is trading 1.3% above its estimated GF Value™ of MAD1,331.32. GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.

Key valuation signals for CAS:PRO:

  • Owner Earnings per Share (TTM): 0.00
  • GF Value™: MAD1,331.32 vs. price of MAD1,349.00 (1.3% above fair value)
  • GF Score™: 85/100 with 6 warning signs

No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description

Address Rue N 7, ZI du Sahel, BP 96/97, Berrechid, Had Soualem, MAR, 26400
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
85GF Score

Get the complete analysis for CAS:PRO

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MAD1,349.00
Price
MAD1,331.32
GF Value